Qiagen this past weekend said that it signed separate agreements with Bristol-Myers Squibb and Johns Hopkins University related to next-generation sequencing assay development.
Under one agreement, Qiagen and BMS will initially explore the use of NGS to develop gene expression profiles as predictive or prognostic tools for use with several BMS immuno-oncology therapies. The companies also plan to enter into a further agreement to develop diagnostic products using the jointly developed profiles to expand the use of NGS technology with other BMS immuno-oncology therapies.